Trial Profile
A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 May 2022
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gemcitabine (Primary) ; Doxorubicin
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms GeDDiS
- 26 Jan 2022 Status changed from active, no longer recruiting to completed.
- 16 Jul 2020 This trial has been completed in United Kingdom according to European Clinical Trials Database record.
- 04 Sep 2017 Results published in the Lancet Oncology